Rhumbline Advisers Raises Stock Holdings in Chemed Co. (NYSE:CHE)

Rhumbline Advisers raised its position in shares of Chemed Co. (NYSE:CHEGet Rating) by 4.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,502 shares of the company’s stock after acquiring an additional 2,298 shares during the period. Rhumbline Advisers’ holdings in Chemed were worth $27,460,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. AlphaCrest Capital Management LLC increased its position in shares of Chemed by 127.3% during the 1st quarter. AlphaCrest Capital Management LLC now owns 5,156 shares of the company’s stock valued at $2,612,000 after purchasing an additional 2,888 shares during the last quarter. Citigroup Inc. increased its position in shares of Chemed by 12.3% during the 1st quarter. Citigroup Inc. now owns 12,240 shares of the company’s stock valued at $6,201,000 after purchasing an additional 1,341 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of Chemed by 1,036.7% during the 2nd quarter. First Horizon Advisors Inc. now owns 341 shares of the company’s stock valued at $159,000 after purchasing an additional 311 shares during the last quarter. Hightower 6M Holding LLC bought a new position in shares of Chemed during the 1st quarter valued at approximately $226,000. Finally, Keybank National Association OH increased its position in shares of Chemed by 10.1% during the 2nd quarter. Keybank National Association OH now owns 10,989 shares of the company’s stock valued at $5,158,000 after purchasing an additional 1,004 shares during the last quarter. 90.42% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $482.90, for a total transaction of $965,800.00. Following the transaction, the chief executive officer now owns 122,235 shares of the company’s stock, valued at approximately $59,027,281.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, VP Michael D. Witzeman sold 1,300 shares of the stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $482.62, for a total transaction of $627,406.00. Following the transaction, the vice president now owns 1,186 shares of the company’s stock, valued at approximately $572,387.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $482.90, for a total value of $965,800.00. Following the transaction, the chief executive officer now directly owns 122,235 shares in the company, valued at approximately $59,027,281.50. The disclosure for this sale can be found here. Insiders have sold 11,036 shares of company stock valued at $5,393,040 in the last quarter. 4.03% of the stock is owned by insiders.

Chemed Stock Performance

Shares of Chemed stock opened at $513.10 on Thursday. The stock’s fifty day moving average is $466.29 and its two-hundred day moving average is $476.80. The company has a market capitalization of $7.63 billion, a PE ratio of 29.81, a price-to-earnings-growth ratio of 3.91 and a beta of 0.54. The company has a quick ratio of 0.63, a current ratio of 0.67 and a debt-to-equity ratio of 0.13. Chemed Co. has a 52 week low of $430.16 and a 52 week high of $539.87.

Chemed (NYSE:CHEGet Rating) last announced its quarterly earnings data on Monday, October 31st. The company reported $4.74 EPS for the quarter, beating the consensus estimate of $4.65 by $0.09. The company had revenue of $526.47 million for the quarter, compared to the consensus estimate of $527.05 million. Chemed had a return on equity of 44.29% and a net margin of 12.31%. Chemed’s quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.06 EPS. As a group, analysts expect that Chemed Co. will post 18.72 earnings per share for the current year.

Chemed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Monday, November 14th will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 0.30%. The ex-dividend date is Thursday, November 10th. Chemed’s dividend payout ratio (DPR) is presently 8.83%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CHE. StockNews.com downgraded Chemed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 9th. Royal Bank of Canada boosted their target price on Chemed from $541.00 to $545.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd.

Chemed Profile

(Get Rating)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEGet Rating).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.